In both MM cell lines, most markers were upregulated after Narciclasine treatment (Figure 5, Figures S5 and S7), with the most notable fold increases observed for LIPT1 (3.8-fold in MSTO-211H, 4.5-fold in H2052/484), FDX1 (2.9-fold in MSTO-211H, 2.2-fold in H2052/484), and SLC7A5 (2.5-fold in MSTO-211H, and 2.6-fold in H2052/484). The gene discussed is LIPT1; the disease is Miyoshi myopathy.